Significant Reduction of Lung Disease on Baricitinib Therapy in a Patient With COPA Syndrome
Year: 2024
Type: article
Abstract: To the Editor, A 4-year-old girl affected by COPA syndrome with joint and pulmonary involvement [1] was on treatment with baricitinib, a Janus kinase inhibitor, since the age of 2. The arthritis quickly resolved.While she had radiographic evidence of significant lung disease (Figure 1A), she has always been asymptomatic, without digital clubbing, nail ridging or abnormal oxyhemoglobin saturation.
Source: Pediatric Pulmonology
DOI: 10.1002/ppul.27423
Institutions: University of Trieste, IRCCS Materno Infantile Burlo Garofolo
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $4,740
OpenAlex ID: W4404760149